IA
MRKR icon

IFP Advisors’s Marker Therapeutics MRKR Stock Holding History

IFP Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-350
Closed -$30K – 4039
2022
Q4 		$30K Buy
350
+118
+51% +$407 ﹤0.01% 2599
2022
Q3 		$20K Buy
232
+132
+132% +$485 ﹤0.01% 3081
2022
Q2 		$9K Hold
100
– – ﹤0.01% 3470
2022
Q1 		$9K Buy
+100
New +$571 ﹤0.01% 3470
2017
Q1 		– Sell
-8
Closed – – 4077
2016
Q4 		$0 Buy
+8
New +$372 ﹤0.01% 4074

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFP Advisors's MRKR Position: Q1 2023 in Review

IFP Advisors sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 350 shares — an estimated $30K sold.

IFP Advisors first reported a position in MRKR in Q4 2016 and held it in 5 quarters. The position peaked at $30K in Q4 2022. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • IFP Advisors reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • IFP Advisors sold 350 Marker Therapeutics shares in Q1 2023, an estimated $30K.
  • IFP Advisors first reported a position in Marker Therapeutics in Q4 2016 and held it in 5 quarters.
  • IFP Advisors's Marker Therapeutics position peaked at $30K in Q4 2022.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.